当代医学
噹代醫學
당대의학
CHINA CONTEMPORARY MEDICINE
2013年
3期
140-141
,共2页
胸腺五肽%结核%免疫功能%痰菌
胸腺五肽%結覈%免疫功能%痰菌
흉선오태%결핵%면역공능%담균
Five thymus peptide%Tuberculosis%Immune function%Sputum
目的分析胸腺五肽对初治结核患者免疫功能以及痰菌阴转率的影响.方法选取2009年4月~2011年4月收治的阳性肺结核患者86例,按照随机抽取的方式划分为观察组和对照组,各43例,观察比较两组治疗前后免疫指标的变化和治疗后的痰菌阴转率.结果观察组1、2个月转阴率分别为74.4%、100%;对照组1、2个月转阴率分别为44.2%、90.7%,两组治疗后2个月内的阴转率比较差异有统计学意义(χ2=18.89,7.77,P<0.05).结论胸腺五肽能够有效改善肺结核患者免疫功能,加速患者痰菌转阴进程,且无显著不良反应,整个临床治疗效果安全且可靠.
目的分析胸腺五肽對初治結覈患者免疫功能以及痰菌陰轉率的影響.方法選取2009年4月~2011年4月收治的暘性肺結覈患者86例,按照隨機抽取的方式劃分為觀察組和對照組,各43例,觀察比較兩組治療前後免疫指標的變化和治療後的痰菌陰轉率.結果觀察組1、2箇月轉陰率分彆為74.4%、100%;對照組1、2箇月轉陰率分彆為44.2%、90.7%,兩組治療後2箇月內的陰轉率比較差異有統計學意義(χ2=18.89,7.77,P<0.05).結論胸腺五肽能夠有效改善肺結覈患者免疫功能,加速患者痰菌轉陰進程,且無顯著不良反應,整箇臨床治療效果安全且可靠.
목적분석흉선오태대초치결핵환자면역공능이급담균음전솔적영향.방법선취2009년4월~2011년4월수치적양성폐결핵환자86례,안조수궤추취적방식화분위관찰조화대조조,각43례,관찰비교량조치료전후면역지표적변화화치료후적담균음전솔.결과관찰조1、2개월전음솔분별위74.4%、100%;대조조1、2개월전음솔분별위44.2%、90.7%,량조치료후2개월내적음전솔비교차이유통계학의의(χ2=18.89,7.77,P<0.05).결론흉선오태능구유효개선폐결핵환자면역공능,가속환자담균전음진정,차무현저불량반응,정개림상치료효과안전차가고.
Objective To study and analysis of thymic peptide five relative to the initial treatment of tuberculosis patients immune function and sputum conversion rate influence. Methods In our hospital from 2009 April to 2011 April were a total of 86 cases of pulmonary tuberculosis with positive, according to randomly divided into the observation group and the control group, 43 cases each, were compared between the two groups before and after treatment, the changes of immunological indexes and after treatment of sputum negative conversion rate. Results The observation group 1, 2 months of negative rates were 74.4%, 100%; control group 1, 2 months of negative rates were 44.2%, 90.7%, two group therapy 2 months after seroconversion rate had a significant difference (χ2=18.89, 7.77, P<0.05). Conclusion Thymic peptide five can effectively improve the immunologic function of patients with pulmonary tuberculosis, is accelerated in patients with sputum negative conversion process, and no obvious adverse reactions, the clinical therapeutic effect of safe and reliable.